SINT SINTX TECHNOLOGIES INC.

SINTX Technologies to Explore Strategic Opportunities

SINTX Technologies to Explore Strategic Opportunities

Salt Lake City, Utah., June 18, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”) today announced that its Board of Directors has initiated a process to explore potential strategic options for the Company.

SINTX has multiple business lines focused on technical materials, with manufacturing and R&D sites located in Salt Lake City and Millersville, MD. In addition to its FDA-approved silicon nitride ceramic spinal fusion devices, the Company has developed ceramic-polymer composites, a novel technology that addresses other medical devices, such as implants for lower extremity fusion. Based on extensive peer-reviewed published data, the key advantages of the Company’s proprietary medical-grade silicon nitride include its proven biocompatibility, inherent resistance to bacteria and viruses, bone cell stimulation, and ease of radiographic imaging. More recently, the Company’s femoral head technology has attracted renewed interest from several global partners. The Company’s silicon nitride is also being utilized in several aerospace engine applications, with two long-term supply agreements in this market.

SINTX also has unique capabilities in 3D printing technologies including Digital Light Projection (DLP) ceramic additive manufacturing, proprietary resin formulations, and extensive pre-print and post-print processing and characterization. The Company has applied Chemical Vapor Infiltration (CVI) and Chemical Vapor Deposition (CVD) manufacturing processes to produce thermal and environmental barrier coatings. These technologies are relevant to many industrial and defense applications, such as hypersonic projectiles, and renewable energy. The company is also one of the few manufacturers of optical ceramic materials for sensor applications. Other proprietary technologies include the manufacture of high performance, lower cost ballistic materials for opaque armor applications at its subsidiary, SINTX Armor. SINTX Armor is expected to begin production of a competitively priced body- and vehicle-protective armor product that has undergone successful testing.

“With technologies targeted at the medical, defense, and renewable energy markets, year-over-year growth in revenues, and other commercial opportunities in the pipeline, SINTX will require additional investment and resources. As such, we want to examine all strategic opportunities targeted at maximizing shareholder value,” said Sonny Bal, Chief Executive Officer and Chairman of SINTX. “We believe that potential partners will find significant value in SINTX’s businesses and capabilities.”

The Company has retained Ascendiant Capital Markets, LLC (), as its exclusive strategic advisor to assist the Board in the review process. Interested parties may reach out to Scott Patten, Managing Director, at for further discussion.

There can be no assurance that the strategic process will result in the Company pursuing any particular transaction or outcome. The SINTX Board has not set a timetable for completion of this process, and it will not disclose further developments until such time that the Company determines that further disclosure is appropriate or necessary.

About SINTX Technologies, Inc.

SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter into new markets. The Company has manufacturing and R&D facilities in Utah and Maryland.

For more information on SINTX Technologies or its materials platform, visit .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurance that the company will enter into a strategic transaction or any transaction at all or that if the company does enter into a transaction that shareholder value will be maximized. A discussion of additional risks and uncertainties can be found in SINTX's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2024, and in SINTX's other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

Business and Media Inquiries for SINTX:

SINTX Technologies

801.839.3502



EN
18/06/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SINTX TECHNOLOGIES INC.

 PRESS RELEASE

SINTX Technologies Announces Launch of OsseoSculpt™ an Advanced Biolog...

SINTX Technologies Announces Launch of OsseoSculpt™ an Advanced Biologic for Use with SINAPTIC® Foot & Ankle Osteotomy Wedge System Clinical evaluation of the product by design surgeons completed, driving early commercial momentum SALT LAKE CITY, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced ceramic biomedical applications of silicon nitride (Si₃N₄), today announced the execution of a private label agreement to supply OsseoSculpt™, a next-generation biologic designed to complement the Company’s FDA 510(K) ...

 PRESS RELEASE

SINTX 테크놀로지스, SINAPTIC® 발·발목 임플란트 시스템에 대해 FDA 승인 획득

SINTX 테크놀로지스, SINAPTIC® 발·발목 임플란트 시스템에 대해 FDA 승인 획득 미국 FDA 승인 및 현지 제조 기반 임플란트 시스템으로, SINTX는 수십억 달러 규모의 미국 시장 진입 본격화 유타주 솔트레이크시티, Utah, Oct. 21, 2025 (GLOBE NEWSWIRE) -- 실리콘 나이트라이드(Si₃N₄)의₄) 의학 응용을 전문으로 하는 첨단 세라믹 선도 기업인 SINTX Technologies, Inc. (나스닥: SINT, 이하 ‘SINTX’ 또는 ‘회사’)가 자사의 SINAPTIC® 발·발목 절골 웨지 시스템 (SINAPTIC® Foot & Ankle Osteotomy Wedge System) 이 미국 식품의약국(FDA)으로부터 510(k) 허가를 획득했다고 오늘 발표했다. 이로써 SINTX는 미국 내 재건적 발·발목 수술 시장에 본격 진출하게 되었으며, 회사는 2026년 1분기 미국 상용 출시를 계획하고 있다. SINTX는 미국 내 제조 역량을 기반으로 수익 가속화와 운영 효율성 제고를 추진할 방침이다. SINAPTIC 임플란트 시스템은 SINTX의 독자적인 실리콘 나이트라이드 생체소재(biomaterial)와 ...

 PRESS RELEASE

SINTX Technologies Menerima Kelulusan FDA untuk SINAPTIC® Foot & Ankle...

SINTX Technologies Menerima Kelulusan FDA untuk SINAPTIC® Foot & Ankle Implant System Sistem implan yang diluluskan oleh FDA dan dikilangkan di Amerika Syarikat membuka peluang bagi SINTX untuk menembusi pasaran bernilai berbilion dolar negara itu SALT LAKE CITY, Utah, Oct. 21, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” atau “Syarikat”), peneraju dalam teknologi seramik canggih yang mengkhusus dalam aplikasi bioperubatan silikon nitrida (Si₃N₄), hari ini mengumumkan bahawa AS Food and Drug Administration (FDA) telah memberikan kelulusan 510(k) untuk SINAPTI...

 PRESS RELEASE

SINTX Technologies Recebe Autorização da FDA para Sistema de Implantes...

SINTX Technologies Recebe Autorização da FDA para Sistema de Implantes de Pé e Tornozelo SINAPTIC® A FDA liberou o sistema de implante fabricado nos EUA, posicionando a SINTX para entrar no mercado bilionário do país SALT LAKE CITY, Utah, Oct. 20, 2025 (GLOBE NEWSWIRE) -- A SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” ou a “Empresa”), líder em cerâmica avançada especializada em aplicações biomédicas de nitreto de silício (Si₃N₄), anunciou hoje a liberação da U.S. Food and Drug Administration (FDA) 510(k) do Sistema de Cunha de Osteotomia de Pé e Tornozelo SINAPTIC®, permitindo a entr...

 PRESS RELEASE

SINTX Technologies ได้รับการรับรองจาก FDA สำหรับระบบปลูกถ่ายเท้าและข้อ...

SINTX Technologies ได้รับการรับรองจาก FDA สำหรับระบบปลูกถ่ายเท้าและข้อเท้า SINAPTIC® ระบบปลูกถ่ายที่ผ่านการรับรองจาก FDA และผลิตในสหรัฐฯ ส่งผลให้ SINTX อยู่ในสถานะที่พร้อมบุกตลาดมูลค่าพันล้านดอลลาร์ในสหรัฐฯ ซอลต์เลกซิตี, ยูทาห์ , Oct. 21, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” หรือ “บริษัท”) ผู้นำด้านเซรามิกขั้นสูงที่เชี่ยวชาญการประยุกต์ใช้ซิลิคอนไนไตรด์ (Si₃N₄) ในทางชีวการแพทย์ ได้ประกาศในวันนี้ว่าได้รับการอนุมัติ 510(k) จาก Food and Drug Administration (FDA) สำหรับ ระบบ SINAPTIC® Foot & Ankle Osteotomy Wedge ซึ่งเปิดทางให้ SINTX เข้าสู่ตลาดการผ่าตัดสร...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch